Pfizer Inc (PFE)

PFE on New York Consolidated

31 Aug 2015
Change (% chg)

$-0.28 (-0.86%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for PFE


Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX,... (more)


Beta: 0.88
Market Cap(Mil.): $201,425.59
Shares Outstanding(Mil.): 6,167.35
Dividend: 0.28
Yield (%): 3.43


  PFE Industry Sector
P/E (TTM): 23.16 35.90 36.13
EPS (TTM): 1.41 -- --
ROI: 6.24 15.37 14.83
ROE: 12.43 15.94 15.69
Search Stocks

EU mergers and takeovers (Aug 18)

BRUSSELS, Aug 18 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:

18 Aug 2015

Shire seen having wiggle room on price in $30 billion Baxalta battle

LONDON - Baxalta wants Shire to improve on its $30 billion bid significantly before it will engage in talks, while its Dublin-based rival could sweeten its offer if it gets to see the U.S. biotech company's books, according to sources on both sides.

13 Aug 2015

Plaintiffs' attorneys to get $67 mln in Pfizer securities deal

- A Manhattan federal judge has awarded plaintiffs' attorneys in a securities class action against drugmaker Pfizer Inc over off-label marketing more than $67 million in fees and expenses from a $400 million settlement reached in January.

12 Aug 2015

UPDATE 1-Shire steps up drive to get Baxalta talking after $30 bln bid

* Baxalta CEO says can get to Shire bid value on its own (Adds Baxalta CEO comments, paragraphs 4, 13 and 14)

10 Aug 2015

Shire CEO steps up drive to get Baxalta board talking

LONDON, Aug 10 - Shire Chief Executive Flemming Ornskov is stepping up his campaign to get Baxalta to the negotiating table as he pushes the benefits a $30 billion takeover offer to the U.S. biotech company's shareholders.

10 Aug 2015

PRESS DIGEST- British Business - Aug 7

Aug 7 - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.

06 Aug 2015

Britain raps Pfizer over huge jump in epilepsy drug price

Britain's competition watchdog has accused Pfizer and Flynn Pharma of breaching UK and European law by ramping up the cost of an epilepsy drug, given to more than 50,000 British patients, by as much as 2,600 percent.

06 Aug 2015

UPDATE 3-Britain raps Pfizer over huge jump in epilepsy drug price

* Pfizer says drug had previously been unprofitable (Adds Pfizer comment on drug's profitability)

06 Aug 2015

EU mergers and takeovers (Aug 5)

BRUSSELS, Aug 5 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:

05 Aug 2015

Pfizer wins EU approval for $15 billion Hospira buy

BRUSSELS - U.S. drugmaker Pfizer gained European Union antitrust approval on Tuesday for its proposed $15 billion acquisition of U.S. rival Hospira after pledging to sell some drugs to allay competition concerns.

04 Aug 2015


  Price Chg
Johnson & Johnson (JNJ.N) $94.75 -0.42
Novartis AG (NOVN.VX) CHF94.35 +0.15
Merck & Co., Inc. (MRK.N) $54.06 -1.31
Roche Holding Ltd. (ROG.VX) CHF262.60 -0.60
Abbott Laboratories (ABT.N) $45.98 -0.04
Bayer AG (BAYGn.DE) €120.90 -0.60
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €88.02 -0.42
AstraZeneca plc (AZN.L) 4,120.00p +36.00
GlaxoSmithKline plc (GSK.L) 1,340.50p +9.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
Provider : Wright Reports
Provider : New Constructs, LLC
Provider : ValuEngine, Inc.
Provider : S&P Capital IQ – STARS Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks